Aethlon Medical, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Frakes
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 11555 Sorrento Valley Road San Diego CA United States of America 92121
- IPO Date
- Mar 4, 1999
- CIK
- 0000882291
- Website
- aethlonmedical.com
- Similar Companies
- Business
- Aethlon Medical, Inc. (Nasdaq: AEMD) develops immunotherapeutic medical devices to treat cancer and life-threatening infectious diseases. The company offers the Hemopurifier, a clinical-stage extracorporeal device that employs lectin-based affinity technology, including Galanthus nivalis agglutinin (GNA), to remove cancer-promoting exosomes, extracellular vesicles, and circulating viruses from blood; applications target oncology in combination with anti-PD-1 therapies such as pembrolizumab (Keytruda) or nivolumab (Opdivo), viral infections without approved treatments, and organ transplantation. The United States Food and Drug Administration designates the Hemopurifier as a Breakthrough Device for advanced or metastatic cancers unresponsive to standard therapies where exosomes contribute to disease and for life-threatening viruses lacking approved options. Aethlon Medical, founded in 1984 and headquartered at 11555 Sorrento Valley Road, Suite 203, San Diego, California, conducts operations primarily in the United States through clinical development and maintains a subsidiary, Aethlon Medical Australia Pty Ltd, to advance Hemopurifier trials in oncology. Recent developments include a positive Data Safety Monitoring Board review in July 2025 recommending advancement to the next cohort without modification in the ongoing safety, feasibility, and dose-finding trial (AEMD-2022-06) of the Hemopurifier in solid tumor patients on pembrolizumab or nivolumab in Australia; publication of preclinical data in December 2025 demonstrating GNA affinity Hemopurifier removal of harmful extracellular vesicles; pricing of a $4.5 million public offering in September 2025 comprising 5 million shares and warrants; and stockholder approval in November 2025 of a reverse stock split to enhance capital market access.
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Advancements in Novel Immunotherapeutics in The Oncology Battle
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical (NASDAQ:AEMD) Shares Pass Below 200-Day Moving Average – Should You Sell?
Aethlon Medical (NASDAQ:AEMD) Stock Crosses Below 200-Day Moving Average – Here’s Why
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million